12-102855315-C-A

Variant summary

Our verdict is Pathogenic. Variant got 8 ACMG points: 8P and 0B. PS3PM3PP4_Moderate

This summary comes from the ClinGen Evidence Repository: This c.527G>T (p.Arg176Leu) variant in PAH was reported in multiple patients with hyperphenylalaninemia and detected with 11 pathogenic variants (PMID:27121329, 9634518, and 29288420). Experimental studies from two publications have demonstrated this variant to have a deleterious effect (PMID:17924342 and 30037505). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_very-strong, PS3, and PP4_moderate. LINK:https://erepo.genome.network/evrepo/ui/classification/CA114371/MONDO:0009861/006

Frequency

Genomes: 𝑓 0.000066 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000045 ( 0 hom. )

Consequence

PAH
NM_000277.3 missense

Scores

6
6
7

Clinical Significance

Pathogenic reviewed by expert panel P:14O:1

Conservation

PhyloP100: 0.121
Variant links:
Genes affected
PAH (HGNC:8582): (phenylalanine hydroxylase) This gene encodes a member of the biopterin-dependent aromatic amino acid hydroxylase protein family. The encoded phenylalanine hydroxylase enzyme hydroxylates phenylalanine to tyrosine and is the rate-limiting step in phenylalanine catabolism. Deficiency of this enzyme activity results in the autosomal recessive disorder phenylketonuria. [provided by RefSeq, Aug 2017]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 8 ACMG points.

PS3
For more information check the summary or visit ClinGen Evidence Repository.
PM3
For more information check the summary or visit ClinGen Evidence Repository.
PP4
For more information check the summary or visit ClinGen Evidence Repository.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
PAHNM_000277.3 linkuse as main transcriptc.527G>T p.Arg176Leu missense_variant 6/13 ENST00000553106.6 NP_000268.1
PAHNM_001354304.2 linkuse as main transcriptc.527G>T p.Arg176Leu missense_variant 7/14 NP_001341233.1
PAHXM_017019370.2 linkuse as main transcriptc.527G>T p.Arg176Leu missense_variant 6/7 XP_016874859.1

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
PAHENST00000553106.6 linkuse as main transcriptc.527G>T p.Arg176Leu missense_variant 6/131 NM_000277.3 ENSP00000448059 P1
PAHENST00000549111.5 linkuse as main transcriptn.623G>T non_coding_transcript_exon_variant 6/61
PAHENST00000307000.7 linkuse as main transcriptc.512G>T p.Arg171Leu missense_variant 7/145 ENSP00000303500
PAHENST00000551988.5 linkuse as main transcriptn.548G>T non_coding_transcript_exon_variant 5/53

Frequencies

GnomAD3 genomes
AF:
0.0000657
AC:
10
AN:
152108
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.0000242
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000262
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000441
Gnomad OTH
AF:
0.000959
GnomAD3 exomes
AF:
0.0000518
AC:
13
AN:
251160
Hom.:
0
AF XY:
0.0000221
AC XY:
3
AN XY:
135748
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.000203
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000352
Gnomad OTH exome
AF:
0.000326
GnomAD4 exome
AF:
0.0000451
AC:
66
AN:
1461804
Hom.:
0
Cov.:
34
AF XY:
0.0000468
AC XY:
34
AN XY:
727208
show subpopulations
Gnomad4 AFR exome
AF:
0.0000299
Gnomad4 AMR exome
AF:
0.000224
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000405
Gnomad4 OTH exome
AF:
0.000166
GnomAD4 genome
AF:
0.0000657
AC:
10
AN:
152108
Hom.:
0
Cov.:
33
AF XY:
0.0000673
AC XY:
5
AN XY:
74290
show subpopulations
Gnomad4 AFR
AF:
0.0000242
Gnomad4 AMR
AF:
0.000262
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000441
Gnomad4 OTH
AF:
0.000959
Alfa
AF:
0.0000141
Hom.:
0
Bravo
AF:
0.0000529
ESP6500AA
AF:
0.000227
AC:
1
ESP6500EA
AF:
0.000116
AC:
1
ExAC
AF:
0.0000330
AC:
4
EpiCase
AF:
0.000109
EpiControl
AF:
0.0000593

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:14Other:1
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Phenylketonuria Pathogenic:7
Pathogenic, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 22, 2024This sequence change replaces arginine, which is basic and polar, with leucine, which is neutral and non-polar, at codon 176 of the PAH protein (p.Arg176Leu). This variant is present in population databases (rs74486803, gnomAD 0.02%). This missense change has been observed in individual(s) with mild phenylketonuria, classical phenylketonuria and hyperphenylalaninemia (PMID: 8088845, 15464430, 17935162, 23500595, 27121329). ClinVar contains an entry for this variant (Variation ID: 631). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt PAH protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects PAH function (PMID: 17924342, 27121329). For these reasons, this variant has been classified as Pathogenic. -
Pathogenic, no assertion criteria providedclinical testingNatera, Inc.Sep 16, 2020- -
Pathogenic, criteria provided, single submitterclinical testingRevvity Omics, RevvityMar 14, 2022- -
Pathogenic, no assertion criteria providedclinical testingCounsylMar 06, 2017- -
Likely pathogenic, criteria provided, single submitterclinical testingBaylor GeneticsMar 28, 2024- -
Pathogenic, reviewed by expert panelcurationClinGen PAH Variant Curation Expert PanelOct 16, 2020This c.527G>T (p.Arg176Leu) variant in PAH was reported in multiple patients with hyperphenylalaninemia and detected with 11 pathogenic variants (PMID: 27121329, 9634518, and 29288420). Experimental studies from two publications have demonstrated this variant to have a deleterious effect (PMID: 17924342 and 30037505). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_very-strong, PS3, and PP4_moderate. -
Pathogenic, criteria provided, single submitterclinical testingFulgent Genetics, Fulgent GeneticsJul 26, 2021- -
not provided Pathogenic:3Other:1
not provided, no classification providedliterature onlyDeBelle Laboratory for Biochemical Genetics, MUHC/MCH RESEARCH INSTITUTE-- -
Pathogenic, criteria provided, single submitterclinical testingEurofins Ntd Llc (ga)Jul 30, 2015- -
Pathogenic, criteria provided, single submitterclinical testingCenter for Pediatric Genomic Medicine, Children's Mercy Hospital and ClinicsMay 03, 2016- -
Pathogenic, criteria provided, single submitterclinical testingGeneDxDec 18, 2023Considered a mild PAH variant as it is associated with significant residual phenylalanine hydroxylase enzyme activity and has been described in association with mild and moderate PKU and hyperphenylalaninemia (PMID: 17935162, 23500595, 8088845); This variant is associated with the following publications: (PMID: 25087612, 23500595, 34828281, 8088845, 26990548, 31623983, 29997390, 10234516, 27121329, 26210745, 30459323, 31589614, 32668217, 33465300, 29288420, 30037505, 17935162) -
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingAmbry GeneticsAug 27, 2021The c.527G>T (p.R176L) alteration is located in exon 6 (coding exon 6) of the PAH gene. This alteration results from a G to T substitution at nucleotide position 527, causing the arginine (R) at amino acid position 176 to be replaced by a leucine (L). Based on data from gnomAD, the T allele has an overall frequency of 0.01% (15/282552) total alleles studied. This alteration has been reported in the compound heterozygous state with a second PAH alteration in several patients with hyperphenylalaninemia and has been reported as a BH4-responsive alteration (Guldberg, 1994; Zurflüh, 2008; Ohlsson, 2017; Aldámiz-Echevarría, 2016). In addition, another alteration at this position (p.R176Q) has also been reported in affected patients (Desviat, 1999; Aldámiz-Echevarría, 2016; Chen, 2018). This amino acid position is not well conserved in available vertebrate species. In vitro functional studies demonstrate reduced residual PAH enzyme activity in multiple cell systems (Gjetting, 2001; Himmelreich, 2018). The in silico prediction for this alteration is inconclusive. Based on the available evidence, this alteration is classified as pathogenic. -
Hyperphenylalaninemia Pathogenic:1
Pathogenic, no assertion criteria providedliterature onlyOMIMMay 15, 1994- -
See cases Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingLaboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert EinsteinAug 16, 2021ACMG classification criteria: PS3, PM3, PP4 -
6-Pyruvoyl-tetrahydrobiopterin synthase deficiency Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpDec 02, 2020Variant summary: PAH c.527G>T (p.Arg176Leu) results in a non-conservative amino acid change located in the Aromatic amino acid hydroxylase, C-terminal domain (IPR019774) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 5.2e-05 in 251160 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in PAH causing Hyperphenylalaninemia (5.2e-05 vs 0.0079), allowing no conclusion about variant significance. c.527G>T has been reported in the literature in multiple individuals affected with Hyperphenylalaninemia (example Aldamiz-Echevarria_2016). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in 30%-50% of normal PAH activity (Aldamiz-Echevarria_2016). Multiple clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All submitters classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.19
BayesDel_addAF
Uncertain
0.090
D
BayesDel_noAF
Pathogenic
0.19
CADD
Benign
20
DANN
Uncertain
0.99
DEOGEN2
Pathogenic
0.97
D;D
Eigen
Benign
-0.59
Eigen_PC
Benign
-0.58
FATHMM_MKL
Benign
0.37
N
LIST_S2
Benign
0.81
T;T
M_CAP
Pathogenic
0.35
D
MetaRNN
Pathogenic
0.77
D;D
MetaSVM
Pathogenic
1.1
D
MutationAssessor
Uncertain
2.5
M;.
MutationTaster
Benign
1.0
N;N
PrimateAI
Benign
0.25
T
PROVEAN
Pathogenic
-5.0
D;D
REVEL
Uncertain
0.62
Sift
Uncertain
0.029
D;D
Sift4G
Uncertain
0.047
D;T
Polyphen
0.0030
B;.
Vest4
0.60
MVP
0.88
MPC
0.037
ClinPred
0.93
D
GERP RS
0.70
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Varity_R
0.49
gMVP
0.86

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.080
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs74486803; hg19: chr12-103249093; COSMIC: COSV61018040; COSMIC: COSV61018040; API